<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743625</url>
  </required_header>
  <id_info>
    <org_study_id>COV15010232</org_study_id>
    <nct_id>NCT01743625</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV155 Tablets in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show the effectiveness of COV155 compared to placebo in
      subjects with acute moderate to severe pain following bunionectomy surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPID48 (Summed pain intensity difference)</measure>
    <time_frame>48 hours</time_frame>
    <description>48 hour Summed pain intensity difference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of COV155</measure>
    <time_frame>48 hours</time_frame>
    <description>Safety and tolerability to be evaluated with physical exams, vital signs, pulse oximetry, clinical laboratory tests, electrocardiograms, and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of analgesia of COV155 versus placebo</measure>
    <time_frame>48 hours</time_frame>
    <description>Onset of confirmed perceptible pain relief, time to meaningful pain relief, and time to peak pain intensity difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic effects of COV155 versus placebo</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain intensity scores, pain intensity differences, and summed pain intensity differences; pain relief scores and total pain relief; percent responders; mean dosing interval; use of rescue medication; global assessment of subject satisfaction with study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Bunion</condition>
  <arm_group>
    <arm_group_label>COV155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COV155</intervention_name>
    <description>COV155 tablets</description>
    <arm_group_label>COV155</arm_group_label>
    <other_name>MNK155</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Voluntarily provide written informed consent

          -  General good health

          -  18 to 75 years of age

          -  Scheduled for primary unilateral first metatarsal bunionectomy (with no collateral
             procedures)

          -  Body mass index ≤33

          -  Female subjects eligible if

               -  Not pregnant or lactating; not planning to become pregnant for duration of study;

               -  Surgically sterile, or have a monogamous partner who is surgically sterile, or at
                  least 2 years postmenopausal, or practicing acceptable birth control for more
                  than 2 months prior to Screening, during the study and for 1 week following last
                  dose of COV155

          -  Male subjects must be sterile (biologically or surgically) or use reliable birth
             control during the study until at least 1 week after the last dose of COV155

          -  Classified as either Physical Status-1 (PS) or PS-2 by the American Society of
             Anesthetists (ASA) Physical Status Classification System.

          -  Willing to complete pain assessments and clinic visits.

          -  Additional inclusion criterion for randomization into the Double-Blind Phase: Subjects
             must experience postoperative pain intensity score ≥5 on a 0 to 10 Numerical Pain
             Rating Score (NPRS) more than 1 hour, and less than 9 hours after discontinuing the
             nerve block, and at least 30 minutes after the last ice pack has been removed (if
             used).

        Exclusion Criteria

          -  Uncontrolled medical condition, serious intercurrent illness, clinically significant
             general health condition, or extenuating circumstance that may significantly decrease
             study compliance or otherwise preclude study participation

          -  Clinically significant abnormal ECG at Screening

          -  Gastric bypass surgery or gastric band

          -  Previous abdominal surgery within the past year or history of abdominal adhesions,
             known or suspected paralytic ileus

          -  History of any medical condition that would alter the absorption, distribution,
             metabolism or excretion of COV155 including but not limited to severe chronic
             diarrhea, chronic constipation, severe irritable bowel syndrome, or unexplained weight
             loss

          -  History of severe bronchial asthma, hypercarbia, hypoxia or sleep apnea

          -  Certain lab abnormalities

          -  Addison's disease, benign prostatic hyperplasia, or kidney disease

          -  Donated blood or blood components within 3 months prior to Screening or during study

          -  Known allergy/hypersensitivity to any opioid analgesics, anesthetics, acetaminophen,
             non steroidal anti-inflammatory drugs (NSAIDs)

          -  History of intolerance to short term opioid use

          -  Unable to discontinue the use of prohibited medications or a history of substance or
             alcohol abuse within 2 years prior to Screening or a positive quantitative urine drug
             test at Screening

          -  Positive for human immunodeficiency virus, hepatitis B or C

          -  Dysphagia and/or cannot swallow study treatment whole

          -  History of migraine or frequent headaches within the previous 2 years, seizures, or
             are currently taking anticonvulsants

          -  Previously received COV155 in a clinical study, or undergone a bunionectomy within the
             last 3 months

          -  Received any investigational drugs or devices within 4 weeks prior to Screening or
             during study

          -  Active malignancy or history of malignancy within 2 years prior to Screening, other
             than completely eradicated cervical squamous cell carcinoma in situ or basal skin
             cancer

          -  Currently taking neuroleptics or stable doses of a benzodiazepine

          -  Other criteria as specified in the protocol

          -  Additional exclusion criterion for randomization into the Double-Blind Phase: Have
             surgical complications that could compromise the safety of the subject or confound the
             results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trails, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <disposition_first_submitted>October 10, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 10, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 20, 2014</disposition_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

